#USA #Innovation #Waltham #Advanced Instruments #Nova Biomedical

Nova Biomedical and Advanced Instruments Merge as One Brand

In a groundbreaking development that signifies a fresh chapter for the biopharmaceutical and clinical sectors, Advanced Instruments and Nova Biomedical have officially merged under a single brand: Nova Biomedical. This transition, announced on October 15, 2025, positions the newly unified company to deliver enhanced value to customers through innovation and improved operational efficiencies.

What This Means for Customers

By consolidating their strengths, both companies aim to better serve their clientele within the biopharmaceutical market. This merger brings together Advanced Instruments’ expertise in scientific and analytical instrumentation with Nova Biomedical’s proven capabilities in point-of-care testing and critical care analyzers. With more than 65 years of combined experience, the merger is set to streamline processes for customers while boosting the overall quality of care in the healthcare ecosystem.

The new branding, which will be visible across all platforms and products starting mid-October, is designed to reflect a strong commitment to innovation and forward-thinking. Byron Selman, President and CEO of Nova Biomedical, emphasized that the merger is built on shared values, including a dedication to quality and customer focus. He remarked, “Operating under the Nova Biomedical name allows us to amplify our global presence and continue delivering gold-standard solutions to our customers.”

Continued Excellence in Product Offerings

Although Advanced Instruments is transitioning to a product portfolio brand specializing in osmolality testing solutions, it will retain its legacy as a hallmarked name under the Nova Biomedical umbrella. Customers can expect to see the new visual identity shortly, as the company aims to infuse the spirit of progress into every aspect of its operations—from corporate communications to product lines.

Beginning mid-October, customers will notice the Nova Biomedical name and branding reflected in their interactions with the company. This initiative serves not only to modernize the brand but also to symbolize a promising investment in the future of life science innovation, ensuring that both existing and new innovations remain at the forefront of industry standards.

What Stays the Same

It is important to note that while the branding is changing, the underlying legal structures, operational processes, and customer relationships will remain intact. Partners will continue to interact with their existing sales and service contacts as they have in the past, ensuring a seamless transition for all parties involved. Orders and inquiries will continue to be processed as usual, mitigating any potential disruptions during this transition period.

Future Opportunities

As Nova Biomedical embarks on this new journey, the company looks forward to the myriad of opportunities that this merger affords. With a combined expertise and product offering, this new entity is poised to drive innovation and improve patient care across multiple fronts in the global healthcare landscape.

For those looking to keep abreast of the changes and developments, more information is available at www.aicompanies.com/nova-merger. As this merger unfolds, Nova Biomedical remains committed to communication and transparency with all partners involved, confident that this new direction will yield significant benefits across the board.

About the Companies

Advanced Instruments has established itself as a leader in the provision of scientific and analytical instruments, focusing on the biotechnology and clinical sectors. Their extensive product portfolio includes systems for cell counting, osmometers, cryoscopes, and more, showcasing over 65 years of commitment to reliability and quality in the laboratory.

Nova Biomedical, founded in 1976, is renowned for its innovation in point-of-care testing and critical care analyzers, making significant advancements with biosensor technology, allowing healthcare providers to make crucial decisions based on accurate and timely data.

With both organizations now united, the future holds promise not just for the companies involved, but for the entire healthcare community they serve.